Comments on ICER’s Scoping Document for Hypertrophic Cardiomyopathy Therapy

April 30, 2021

An efficacious treatment that reduces the symptoms and risk factors associated with obstructive hypertrophic cardiomyopathy delivers great value to patients. Analyses that fail to consider all of the potential benefits, particularly the quality-of-life and productivity benefits, will undervalue this drug.

Read the Letter

Categorized in: Analysis

◀ Next Post

Previous Post ►